IBM (NYSE: IBM) is working with Diabetizer, a German-based healthcare technology company, to leverage IBM's open platform-as-a-service, Bluemix to build and deploy a first-of-its-kind, cloud-based application that improves care for diabetes patients around the world. The app allows diabetes patients to instantly access and aggregate their health data from multiple devices anywhere in the world, as well as apply advanced analytics to control their blood sugar at precisely accurate levels.
With more than 350 million diabetics worldwide, diabetes remains one of the greatest health challenges of our generation. Working with IBM, Diabetizer is changing the way diabetics cope with managing their disease - many of whom struggle with handwritten plans and blood sugar logs, guessed biometric data, and manual (and often inaccurate) estimates at dosage amounts and times. Using Bluemix, which is powered by a global cloud platform from SoftLayer, an IBM Company, Diabetizer has built a cloud-based, analytics-driven app, which moves seamlessly between mobile and web interfaces to bring new levels of flexibility and precision to patients, allowing them to:
- Aggregate blood sugar, nutritional and health data from multiple input sources (i.e. smart phone and web apps) into one, centralized mobile portal accessible from anywhere in the world - simplifying records and doctor-patient conversations
- Tap into the Internet of Things to directly integrate biometric data from wearable devices, analyzing physical activity along with blood sugar levels to gain a more holistic view of a diabetic's overall health
"Cloud technology has given us the flexibility and power we need to build an app that combines patients' most important records into one, easily usable portal," said Robin Hrassnigg, Diabetizer's founder and managing director. "Combining this centralized data with powerful analytics, we're giving the millions of diabetes sufferers around the world the opportunity for greater mobility, more accurate treatment and more freedom from constant calculations and data logging."
The myDIABETIZER app combines a clear evaluation of blood glucose readings with professional documentation for doctors and diabetologists, automatically importing measurement data and setting key parameters based on individual patient needs. Additionally, the app synchronizes readings taken by blood glucose measuring devices like iBGStar and GlucoDock with patients' smartphones, enabling mobile data analysis with advanced analytics software.
Bluemix is one of the Cloud Foundry Foundation's largest cloud platform implementations, and - since its beta launch in February 2014 - has helped numerous startups such as Diabetizer turn their ideas into mobile and web apps and products.
"Diabetizer, one of the first Bluemix customers in the German-speaking region, is a perfect example of how young companies can take their business ideas forward with a scalable, flexible, global cloud infrastructure," said Sandy Carter, General Manager of Ecosystem Development at IBM. "Using the cloud to quickly build and bring to market solutions such as the myDIABETIZER app brings a new level of agility to the way we develop - allowing us to build apps which can help alleviate some of our most pressing health issues today."
